@article{MTMT:32793328,
	title = {Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes},
	url = {https://m2.mtmt.hu/api/publication/32793328},
	author = {Szeitz, Beáta and Pipek, Orsolya Anna and Kulka, Janina and Szundi, Csilla and Rusz, Orsolya and Tőkés, Tímea and Szász, Attila Marcell and Kovács, Attila and Pesti, Adrián István and Ben Arie, Taya Beri and Gángó, Ambrus and Fülöp, Zsolt and Drágus, Emőke and Vári-Kakas, Stefan A. and Tőkés, Anna-Mária},
	doi = {10.3390/cancers14081942},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {14},
	unique-id = {32793328},
	year = {2022},
	eissn = {2072-6694},
	orcid-numbers = {Szeitz, Beáta/0000-0001-6414-0537; Pipek, Orsolya Anna/0000-0001-8109-0340; Kulka, Janina/0000-0001-6498-5943; Rusz, Orsolya/0000-0001-5726-4072; Tőkés, Tímea/0000-0002-5456-1706; Szász, Attila Marcell/0000-0003-2739-4196; Pesti, Adrián István/0000-0001-6706-6221; Gángó, Ambrus/0000-0001-9127-5015; Fülöp, Zsolt/0000-0002-0854-5617; Tőkés, Anna-Mária/0000-0002-9581-7536}
}

@article{MTMT:33137925,
	title = {Response Evaluation with Dynamic FDG PET/CT during the Primary Systemic Therapy of Breast Cancer - A Case Report},
	url = {https://m2.mtmt.hu/api/publication/33137925},
	author = {Kajary, Kornelia and Lengyel, Zsolt and Tőkés, Anna-Mária and Kulka, Janina and Dank, Magdolna and Tőkés, Tímea},
	doi = {10.31487/j.ACO.2021.01.02},
	journal-iso = {ACO},
	journal = {ANNALS OF CLINICAL ONCOLOGY},
	volume = {4},
	unique-id = {33137925},
	abstract = {18-fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET) and mainly combined with computed tomography (CT), abbreviated as FDG PET/CT is a useful and accurate tool for staging and restaging in locally advanced breast cancer. In daily practice static images are prepared during the PET/CT examinations. However, despite the success of static PET and PET/CT imaging, the role of precise quantification of FDG-uptake – measured by dynamic acquisition – is ambiguous in the staging and management of different malignancies. In this case report, we described our experience with staging, interim and restaging dynamic PET/CT examinations of a woman suffering from breast cancer. Based on the described case we concluded that dynamic PET/CT is suitable for accurate quantification of FDG-uptake in primary breast tumors. However, performing dynamic PET/CT examinations is time-consuming, therefore, it is important to define the group of patients where their use is with the most favourable benefit/risk ratio. Furthermore, using of interim PET/CT scan is recommended in cases with clinically controversial baseline tests. Based on literature in vivo biomarkers of the dynamic PET/CT are predictive of more favourable tumor response and longer disease-free survival, as confirmed by our own results.},
	year = {2021},
	eissn = {2674-3248},
	pages = {1-4},
	orcid-numbers = {Tőkés, Anna-Mária/0000-0002-9581-7536; Kulka, Janina/0000-0001-6498-5943; Dank, Magdolna/0000-0002-4442-8733; Tőkés, Tímea/0000-0002-5456-1706}
}

@article{MTMT:30785775,
	title = {Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.},
	url = {https://m2.mtmt.hu/api/publication/30785775},
	author = {Tőkés, Tímea and Tőkés, Anna-Mária and Szentmártoni, Gyöngyvér and Kiszner, Gergő and Mühl, Dorottya and Molnár, Béla Ákos and Kulka, Janina and Krenács, Tibor and Dank, Magdolna},
	doi = {10.1007/s12253-019-00726-w},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {26},
	unique-id = {30785775},
	issn = {1219-4956},
	abstract = {We aimed to analyze the expression of cell-cycle regulation markers - minichromosome maintenance protein 2 (MCM2), Ki-67, Cyclin-A and phosphohistone-H3 (PHH3) - in pre-treatment core-biopsy samples of breast carcinomas in correlation with known predictive and prognostic factors. Totally 52 core biopsy samples obtained prior to neoadjuvant therapy were analyzed. Immunohistochemistry was performed to analyze the expression of MCM2, Ki-67, Cyclin A and PHH3, which were correlated with the following clinicopathological parameters: clinical TNM, tumor grade, biological subtype, the presence of tumor infiltrating lymphocytes (TIL), pathological tumor response rate to the neoadjuvant therapy and patient survival. All investigated markers showed higher expression in high grade and in triple negative tumors (p < 0.01 and p < 0.05, respectively). Hormone receptor negative tumors showed significantly higher expression of Ki-67 (p < 0.01), MCM2 (p < 0.01) and Cyclin A (p < 0.01) than hormone receptor positive ones. Tumors with increased TIL showed significantly higher Ki-67 expression (p = 0.04). Pattern analysis suggested that novel cell-cycle marker-based subgrouping reveals predictive and prognostic potential. Tumors with high MCM2, Cyclin A or PHH3 expression showed significantly higher rate of pathological complete remission. Tumors with early relapse (progression-free survival ≤2 years) and shortened overall survival also show a higher rate of proliferation. Our cell cycle marker (Ki-67, MCM2, Cyclin A, PHH3) based testing could identify tumors with worse prognosis, but with a favorable response to primary systemic therapy. The pattern of cell-cycle activity could also be useful for predicting early relapse, but our findings need to be further substantiated in larger patient cohorts.},
	keywords = {Cell Cycle; breast cancer; KI67; Primary systemic therapy; cyclin A; MCM; PHH3},
	year = {2020},
	eissn = {1532-2807},
	pages = {1499-1510},
	orcid-numbers = {Tőkés, Tímea/0000-0002-5456-1706; Tőkés, Anna-Mária/0000-0002-9581-7536; Szentmártoni, Gyöngyvér/0000-0003-1093-4619; Kiszner, Gergő/0000-0002-3016-2823; Mühl, Dorottya/0000-0001-7565-8462; Kulka, Janina/0000-0001-6498-5943; Krenács, Tibor/0000-0001-9164-065X; Dank, Magdolna/0000-0002-4442-8733}
}

@article{MTMT:30639011,
	title = {Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer. Clinicopathological Correlations},
	url = {https://m2.mtmt.hu/api/publication/30639011},
	author = {Kajáry, Kornélia and Lengyel, Zsolt and Tőkés, Anna-Mária and Kulka, Janina and Dank, Magdolna and Tőkés, Tímea},
	doi = {10.1007/s12253-019-00641-0},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {26},
	unique-id = {30639011},
	issn = {1219-4956},
	abstract = {Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.},
	keywords = {KINETICS; breast cancer; PET-CT; TUMOR-INFILTRATING LYMPHOCYTES},
	year = {2020},
	eissn = {1532-2807},
	pages = {997-1006},
	orcid-numbers = {Tőkés, Anna-Mária/0000-0002-9581-7536; Kulka, Janina/0000-0001-6498-5943; Dank, Magdolna/0000-0002-4442-8733; Tőkés, Tímea/0000-0002-5456-1706}
}

@article{MTMT:30639008,
	title = {Comparison of different motion correction techniques for dynamic FDG-PET/CT studies in breast cancer patients.},
	url = {https://m2.mtmt.hu/api/publication/30639008},
	author = {Tőkés, Tímea and Dank, Magdolna and Lengyel, Zsolt and Kajáry, Kornélia},
	doi = {10.23736/S1824-4785.19.03114-5},
	journal-iso = {Q J NUCL MED MOL IM},
	journal = {QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
	volume = {64},
	unique-id = {30639008},
	issn = {1824-4785},
	abstract = {Our aim was evaluate interchangeability of different motion correction methods in the assessment of dynamic FDG-PET/CT studies in breast cancer patients as well as to assess the interrater reliability of these methods.In our prospective study we included patients with malignant breast tumours. Dynamic PET acquisition lasted for 60 minutes after tracer (FDG) injection. Every study was assessed by the same two experienced observers. We assessed plasma activity noninvasively. In case of the primary tumour VOIs we applied two different approaches to correct motion artefacts: Method I) frame-by-frame manual motion correction; Method II) frame-by-frame semi-automatic software-based motion correction. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate).35 lesions detected during 34 dynamic studies were included in this current analysis. Interrater reliability of both applied motion correction methods proved to be excellent (ICC= 0.89-0.99), except Ki measured by Method I (ICC=0.66). Bland-Altman analysis revealed that Method II resulted in significantly lower values than Method I regarding k3 and Ki in case of both observers, and regarding MRFDG in one of the observers. In case of K1 and k2 the two methods were in good agreement.Both applied methods proved to be reproducible and reliable, especially Method II, where every measured kinetic parameter showed excellent interrater reliability. Different approaches of motion correction could have a significant effect on the results of the kinetic modelling; therefore careful selection of the most reliable method is advised.},
	year = {2020},
	eissn = {1827-1936},
	pages = {406-413},
	orcid-numbers = {Tőkés, Tímea/0000-0002-5456-1706; Dank, Magdolna/0000-0002-4442-8733}
}

@article{MTMT:30939173,
	title = {18F-FDG-PET/CT SZEREPE A PRIMER SZISZTÉMÁS TERÁPIÁBAN RÉSZESÜLŐ EMLŐDAGANATOS BETEGEK TERÁPIÁS VÁLASZÁNAK MEGHATÁROZÁSÁBAN},
	url = {https://m2.mtmt.hu/api/publication/30939173},
	author = {Török, Judit and Czibor, Sándor and Tőkés, Tímea and Györke, Tamás},
	journal-iso = {MAGYAR RADIOLÓGIA ONLINE},
	journal = {MAGYAR RADIOLÓGIA ONLINE},
	volume = {10},
	unique-id = {30939173},
	year = {2019},
	eissn = {2063-9481},
	pages = {46},
	orcid-numbers = {Török, Judit/0000-0003-4105-2926; Czibor, Sándor/0000-0002-7679-3137; Tőkés, Tímea/0000-0002-5456-1706; Györke, Tamás/0000-0002-8772-9931}
}

@article{MTMT:30855177,
	title = {The role of 18F-FDG-PET/CT in the response evaluation of primary systemic therapy in breast cancer},
	url = {https://m2.mtmt.hu/api/publication/30855177},
	author = {Török, Judit and Czibor, Sándor and Tőkés, Tímea and Györke, Tamás},
	journal-iso = {EUR J NUCL MED MOL I},
	journal = {EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING},
	volume = {46},
	unique-id = {30855177},
	issn = {1619-7070},
	year = {2019},
	eissn = {1619-7089},
	pages = {S525},
	orcid-numbers = {Török, Judit/0000-0003-4105-2926; Czibor, Sándor/0000-0002-7679-3137; Tőkés, Tímea/0000-0002-5456-1706; Györke, Tamás/0000-0002-8772-9931}
}

@book{MTMT:30709143,
	title = {Gyógyulásom Könyve},
	url = {https://m2.mtmt.hu/api/publication/30709143},
	isbn = {9786150042954},
	author = {Bálintné, Pataki Aranka and Brjeska, Dóra and Dank, Magdolna and Dvorákné, Borda Judit and Hajdú, Anett and Horváth, Katalin Beatrix and Juhász, Ágnes and Kleiner, Dénes and Kovács, Eszter and Németh, Zsuzsanna and Petrányi, Ágota Eszter and Tőkés, Tímea},
	editor = {Désfalvi, Judit and Újháziné, Kerék Barbara},
	publisher = {Pink Bolero Önsegítő Egyesület a Mellrák Ellen},
	unique-id = {30709143},
	abstract = {https://gyogyulasomkonyve.hu/
		Régi verzió:
		https://www.gyogyulaskonyvem.hu/mobilbarat/
		https://www.gyogyulasomkonyve.hu/teljes_kiadvany/},
	year = {2019},
	orcid-numbers = {Désfalvi, Judit/0000-0003-4580-0581; Dank, Magdolna/0000-0002-4442-8733; Kleiner, Dénes/0000-0002-4715-8695; Németh, Zsuzsanna/0000-0003-2586-6639; Tőkés, Tímea/0000-0002-5456-1706}
}

@article{MTMT:30658783,
	title = {Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer},
	url = {https://m2.mtmt.hu/api/publication/30658783},
	author = {Tőkés, Anna-Mária and Rusz, Orsolya and Cserni, Gábor and Tóth, Erika and Rubovszky, Gábor and Tőkés, Tímea and Vízkeleti, Laura and Reiniger, Lilla and Kószó, Renáta Lilla and Kahán, Zsuzsanna and Kulka, Janina and Donia, Marco and Vörös, András and Szállási, Zoltán},
	doi = {10.1080/0284186X.2019.1633015},
	journal-iso = {ACTA ONCOL},
	journal = {ACTA ONCOLOGICA},
	volume = {58},
	unique-id = {30658783},
	issn = {0284-186X},
	year = {2019},
	eissn = {1651-226X},
	pages = {1603-1611},
	orcid-numbers = {Tőkés, Anna-Mária/0000-0002-9581-7536; Rusz, Orsolya/0000-0001-5726-4072; Cserni, Gábor/0000-0003-1344-7744; Tóth, Erika/0000-0003-2054-8447; Rubovszky, Gábor/0000-0003-1723-5589; Tőkés, Tímea/0000-0002-5456-1706; Vízkeleti, Laura/0000-0001-6870-3499; Reiniger, Lilla/0000-0003-2248-4264; Kószó, Renáta Lilla/0000-0002-1958-7839; Kahán, Zsuzsanna/0000-0002-5021-8775; Kulka, Janina/0000-0001-6498-5943; Vörös, András/0000-0001-6837-0567; Szállási, Zoltán/0000-0001-5395-7509}
}

@article{MTMT:3200423,
	title = {Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.},
	url = {https://m2.mtmt.hu/api/publication/3200423},
	author = {Ács, Balázs and Zambo, V and Vízkeleti, Laura and Szász, Attila Marcell and Madaras, Lilla and Szentmártoni, Gyöngyvér and Tőkés, Tímea and Molnár, Béla Ákos and Molnár, István Artúr and Vari-Kakas, S and Kulka, Janina and Tőkés, Anna-Mária},
	doi = {10.1186/s13000-017-0608-5},
	journal-iso = {DIAGN PATHOL},
	journal = {DIAGNOSTIC PATHOLOGY},
	volume = {12},
	unique-id = {3200423},
	issn = {1746-1596},
	abstract = {BACKGROUND: Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a prognostic factor in partial responder/non-responder groups remains uncertain. METHODS: One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study. The optimal cut-off value for Ki-67 labeling index (LI) to discriminate response to treatment was assessed by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier curve estimation, log-rank test and cox regression analysis were carried out to reveal the association between Ki-67 categories and survival (DMFS = Distant metastases-free survival, OS = Overall survival). RESULTS: Twenty three out of 120 patients (19.2%) achieved pathologic complete remission (pCR), whereas partial remission (pPR) and no response (pNR) to neoadjuvant chemotherapy (NAC) was detected in 60.8% and 20.0%, respectively. The distribution of subtypes showed a significant difference in pathological response groups (p < 0.001). Most of the TNBC cases were represented in pCR group. The most relevant cut-off value for the Ki-67 distinguishing pCR from pNR cases was 20% (p = 0.002). No significant threshold for Ki-67 was found regarding DMFS (p = 0.208). Considering OS, the optimal cut-off point occurred at 15% Ki-67 (p = 0.006). The pPR group represented a significant Ki-67 threshold at 30% regarding OS (p = 0.001). Ki-67 and pPR subgroups were not significantly associated (p = 0.653). For prognosis prediction, Ki-67 at 30% cut-off value (p = 0.040) furthermore subtype (p = 0.037) as well as pathological response (p = 0.044) were suitable to separate patients into good and unfavorable prognosis cohorts regarding OS. However, in multivariate analyses, only Ki-67 at 30% threshold (p = 0.029), and subtype (p = 0.008) were independently linked to OS. CONCLUSIONS: NAC is more efficient in tumors with at least 20% Ki-67 LI. Both Ki-67 LI and subtype showed a significant association with pathological response. Ki-67 LI represented independent prognostic potential to OS in our neoadjuvant patient cohort, while pathological response did not. Additionally, our data also suggest that if a tumor is non-responder to NAC, increased Ki-67 is a poor prognostic marker.},
	keywords = {Aged; Adult; Female; Middle Aged; Humans; immunohistochemistry; Prognosis; Retrospective Studies; Cohort Studies; Cross-Sectional Studies; Chemotherapy, Adjuvant; ROC Curve; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Disease-Free Survival; Proportional Hazards Models; Area Under Curve; Kaplan-Meier Estimate; Ki-67 Antigen/*analysis; *Neoadjuvant Therapy; Biomarkers, Tumor/analysis; Breast Neoplasms/drug therapy/mortality/*pathology},
	year = {2017},
	eissn = {1746-1596},
	orcid-numbers = {Ács, Balázs/0000-0002-0972-4633; Vízkeleti, Laura/0000-0001-6870-3499; Szász, Attila Marcell/0000-0003-2739-4196; Madaras, Lilla/0000-0002-4137-4696; Szentmártoni, Gyöngyvér/0000-0003-1093-4619; Tőkés, Tímea/0000-0002-5456-1706; Kulka, Janina/0000-0001-6498-5943; Tőkés, Anna-Mária/0000-0002-9581-7536}
}